43 related articles for article (PubMed ID: 20016369)
1. Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Dellas K; Reese T; Richter M; Arnold D; Dunst J
Radiat Oncol; 2012 Jun; 7():83. PubMed ID: 22681700
[TBL] [Abstract][Full Text] [Related]
2. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; Lu M; Yu JW; Li YY; Shen L
BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
[TBL] [Abstract][Full Text] [Related]
3. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
Li KM; Rivory LP; Hoskins J; Sharma R; Clarke SJ
Br J Clin Pharmacol; 2007 Jan; 63(1):67-74. PubMed ID: 16827816
[TBL] [Abstract][Full Text] [Related]
4. The dual role of thymidine phosphorylase in cancer development and chemotherapy.
Bronckaers A; Gago F; Balzarini J; Liekens S
Med Res Rev; 2009 Nov; 29(6):903-53. PubMed ID: 19434693
[TBL] [Abstract][Full Text] [Related]
5. A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs.
Wetzel S; Fidel J; Whittington D; Villarino NF
BMC Vet Res; 2024 Jan; 20(1):36. PubMed ID: 38297307
[TBL] [Abstract][Full Text] [Related]
6. Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.
He X; Lan H; Jin K; Liu F
Front Immunol; 2023; 14():1237764. PubMed ID: 37790928
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.
Grumetti L; Lombardi R; Iannelli F; Pucci B; Avallone A; Di Gennaro E; Budillon A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158962
[TBL] [Abstract][Full Text] [Related]
8. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
[TBL] [Abstract][Full Text] [Related]
9. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.
Che J; Pan L; Yang X; Liu Z; Huang L; Wen C; Lin A; Liu H
Mol Clin Oncol; 2017 Dec; 7(6):943-952. PubMed ID: 29285354
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic resistance in colorectal cancer: a review.
Hammond WA; Swaika A; Mody K
Ther Adv Med Oncol; 2016 Jan; 8(1):57-84. PubMed ID: 26753006
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
Panczyk M
World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
[TBL] [Abstract][Full Text] [Related]
12. Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Jiang WQ; Fu FF; Li YX; Wang WB; Wang HH; Jiang HP; Teng LS
J Zhejiang Univ Sci B; 2012 Sep; 13(9):663-75. PubMed ID: 22949358
[TBL] [Abstract][Full Text] [Related]
13. Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report.
Giunta G
Case Rep Med; 2010; 2010():426804. PubMed ID: 20671989
[TBL] [Abstract][Full Text] [Related]
14. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Petrioli R; Bargagli G; Lazzi S; Pascucci A; Francini E; Bellan C; Conca R; Martellucci I; Fiaschi AI; Lorenzi B; Francini G;
Anticancer Drugs; 2010 Mar; 21(3):313-9. PubMed ID: 20016369
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
16. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS
J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
19. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Bonotto M; Bozza C; Di Loreto C; Osa EO; Poletto E; Puglisi F
Clin Breast Cancer; 2013 Jun; 13(3):167-72. PubMed ID: 23218471
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
